person · Reporting owner

Coy Travis Alan

Disclosed activity across 2 companies

Tapewire entity: 65666
SEC CIK: 0001969524

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Immunocore Holdings plcIMCR · Entity 4544	Chief Financial Officer	February 17, 2026	February 19, 2026
TRex Bio, Inc.TRXB · Entity 184308	Director	October 08, 2026	October 09, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Immunocore Holdings plc

Report date February 17, 2026 · Filed February 19, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Share UnitsSEC Table II · derivative / convertible security	Direct	33,353	Reported balance After 2026-02-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-02-17 · Grant · Acquired 33,353 · Balance 33,353 F1: Each restricted share unit ("RSU") represents a contingent right to receive one Ordinary Share. F2: The RSUs vest in four equal annual installments beginning February 17, 2027, subject to the Reporting Person's continuous service through each such vesting date. F3: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share.
Employee Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.38 · Expires 2036-02-16	Direct	95,637	Reported balance After 2026-02-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-02-17 · Grant · Acquired 95,637 · Balance 95,637 F4: 25% of the shares subject to the option award shall vest on February 17, 2027, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. F3: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted share unit ("RSU") represents a contingent right to receive one Ordinary Share.

F2: The RSUs vest in four equal annual installments beginning February 17, 2027, subject to the Reporting Person's continuous service through each such vesting date.

F3: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share.

F4: 25% of the shares subject to the option award shall vest on February 17, 2027, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

TRex Bio, Inc.

Report date October 08, 2026 · Filed October 09, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2036-10-08	Direct	17,500	Reported balance After 2026-10-08 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-10-08 · Grant · Acquired 17,500 · Balance 17,500 F1: The option vests in full on October 8, 2027, subject to the reporting person's continued service through such date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in full on October 8, 2027, subject to the reporting person's continued service through such date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 08, 2026 Filed Oct 9, 2026 01:53 UTC	TRex Bio, Inc. TRXB · Entity 184308	GrantStock Option (Right to Buy) · Derivative	17,500	$0.00 Strike: $14.00	$0.00	Disclosure SEC source: 0001193125-26-418298 · ownership.xml · derivative · entry 1 Coy Travis Alan · CIK 0001969524 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2036-10-08 F1 · derivative.exercise_date: The option vests in full on October 8, 2027, subject to the reporting person's continued service through such date. Read SEC document
February 17, 2026 Filed Feb 19, 2026 22:00 UTC	Immunocore Holdings plc IMCR · Entity 4544	GrantEmployee Share Option (Right to Buy) · Derivative	95,637	$0.00 Strike: $32.38	$0.00	Disclosure SEC source: 0001969524-26-000002 · form4-02192026_100225.xml · derivative · entry 2 Coy Travis Alan · CIK 0001969524 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,637 Underlying: Ordinary Shares · 95,637 shares Expires 2036-02-16 F4 · derivative.exercise_date: 25% of the shares subject to the option award shall vest on February 17, 2027, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. F3 · derivative.underlying: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. Read SEC document
February 17, 2026 Filed Feb 19, 2026 22:00 UTC	Immunocore Holdings plc IMCR · Entity 4544	GrantRestricted Share Units · Derivative	33,353	$0.00	$0.00	Disclosure SEC source: 0001969524-26-000002 · form4-02192026_100225.xml · derivative · entry 1 Coy Travis Alan · CIK 0001969524 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,353 Underlying: Ordinary Shares · 33,353 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit ("RSU") represents a contingent right to receive one Ordinary Share. F2 · derivative.exercise_date: The RSUs vest in four equal annual installments beginning February 17, 2027, subject to the Reporting Person's continuous service through each such vesting date. F2 · derivative.expiration_date: The RSUs vest in four equal annual installments beginning February 17, 2027, subject to the Reporting Person's continuous service through each such vesting date. F3 · derivative.underlying: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. Read SEC document
January 01, 2025 Filed Jan 3, 2025 21:08 UTC	Immunocore Holdings plc IMCR · Entity 4544	GrantEmployee Share Option (Right to Buy) · Derivative	274,033	$0.00 Strike: $29.50	$0.00	Disclosure SEC source: 0001415889-25-000390 · form4-01032025_090124.xml · derivative · entry 1 Coy Travis Alan · CIK 0001969524 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 274,033 Underlying: Ordinary Shares · 274,033 shares Expires 2034-12-31 F1 · derivative.exercise_date: 25% of the shares subject to the option award shall vest on January 1, 2026, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.